Abstract
Beginning with my concept in 1969 to treat disease at the nucleic acid level using antisense nucleic acids, antisense has evolved to the current Morpholino oligos. Morpholinos have been the dominant gene knockdown system in developmental biology. Lack of delivery technologies has limited their use in adult animals (including humans), though alteration in muscles in Duchenne muscular dystrophy (DMD) allows delivery into adult muscle. Morpholinos are currently in Phase 3 clinical trials for DMD and a Morpholino oligo for skipping dystrophin exon 51 has been approved by the US FDA. With improved delivery techniques, such as those in development at Gene Tools, therapeutic Morpholinos for many difficult-to-treat diseases will be possible. Initial applications are expected to be custom cocktails of delivery-enabled Morpholinos for treating cancers.
Key words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ekker S (2000) Morphants: a new systematic vertebrate functional genomics approach. Yeast 17:302–306
Heasman J (2002) Morpholino oligos: making sense of antisense? Dev Biol 243:209–214
SPECIAL ISSUE (2001) Morpholino gene knockdowns – all 27 research reports in the July issue of the journal Genesis 30:89–200
Summerton J (1979) Intracellular inactivation of specific nucleotide sequences: a general approach to the treatment of viral diseases and viral-mediated cancers. J Theor Biol 78:77–99
Summerton J (1979) Sequence-specific crosslinking agents for nucleic acids: design and functional group testing. J Theor Biol 78:61–75
Summerton J, Hoenig S, Butler C, Chvapil M (1977) The mechanism of hemolysis by silica and its bearing on silicosis. Exp Mol Pathol 26:113–128
Summerton J, Bartlett P (1978) Sequence-specific crosslinking agents for nucleic acids. Use of 6-bromo-5,5dimethoxyhexanohydrazide for crosslinking cytidine to guanosine and crosslinking RNA to complementary sequences of DNA. J Mol Biol 122:145–162
Stephenson M, Zamecnik P (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 75:285–288
Zamecnik P, Stephenson M (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 75:280–284
Miller PS, Yano J, Yano E, Carroll C, Jayaraman K, Ts’o POP (1979) Nonionic nucleic acid analogues. Synthesis and characterization of didexoyribonucleoside methylphosphonates. Biochemistry 18:5134–5143
Miller PS, Agris CH, Blake KR, Murakami A, Spitz SA, Reddy MP, Ts’o POP (1983) Nonionic oligonucleoside analogs as new tools for studies on the structure and function of nucleic acids inside living cells. In: Pullman B, Jortner J (eds) Nucleic acids: the vectors of life. D. Reidel Publishing, Dordrecht, p 521
Blake KR, Murakami A, Spitz SA, Glave SA, Reddy MP, Ts’o POP, Miller PS (1985) Hybridization arrest of globin synthesis in rabbit reticulocyte cells by oligodeoxyribonucleoside methylphosphonates. Biochemistry 24:6139–6145
Miller P, Barrett J, Ts’o P (1974) Synthesis of oligodeoxyribonucleotide ethylphosphotriesters and their specific complex formation with transfer ribonucleic acid. Biochemistry 13:4887–4986
Stirchak E, Summerton J, Weller D (1987) Uncharged stereoregular nucleic acid analogues. 1. Synthesis of a cytosine-containing oligomer with carbamate internucleoside linkages. J Org Chem 52:4202–4206
Stirchak E, Summerton J, Weller D (1989) Uncharged stereoregular nucleic acid analogues. 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res 17:6129–6141
Summerton J., and Weller D. (1993) Uncharged Morpholino-based polymers having phosphorous containing chiral inter-subunit linkages. US Patent 5,185,444.
Summerton J, Weller D (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 7:187–195
Summerton J, Stein D, Huang S, Matthews P, Weller D, Partridge M (1997) Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 7:63–70
Summerton J (1999) Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1489:141–158
Summerton J (2006) Chapter 6: Morpholinos and PNAs compared. In: Christopher J, Matthew D (eds) Peptide nucleic acids, morpholinos and related antisense biomolecules. Springer, New York, NY, pp 89–113
Summerton J (2007) Morpholinos, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem 7:651–660
Wilczynska A, Bushell M (2015) The complexity of miRNA-mediated repression. Cell Death Differ 22:22–33
Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen JS, Broder S (1987) Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A 84:7706–7710
Agrawal S, Goodchild J, Civeira MP, Thornton AH, Sarin PS, Zamecnik PC (1988) Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci U S A 85:7079–7083
Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE (1993) PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen bonding rules. Nature 365:566–568
Nielsen P, Egholm M (1999) Peptide nucleic acids protocols and applications. Horizon Scientific Press, Norfolk
Nielsen P (2006) Chapter 1: the many faces of PNA. In: Christopher J, Matthew D (eds) Peptide nucleic acids, morpholinos and related antisense biomolecules. Springer, New York, NY, pp 3–17
Elbashir S, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498
Scherer L, Rossi J (2006) Chapter 8: recent applications of RNA interference (RNAi) in mammalian systems. In: Christopher J, Matthew D (eds) Peptide nucleic acids, morpholinos and related antisense biomolecules. Springer, New York, NY, pp 133–147
Gruber J, Manninga H, Tuschl T, Osborn M, Weber K (2005) Specific RNAi mediated gene knockdown in zebrafish cell lines. RNA Biol 2:101–105
Summerton J (2016) Custom cocktail for curing any cancer: a strategy for destroying any cancer without harming the patient. J Drug Discov Dev Deliv 3(1): id 1020
Summerton J (2003) Custom cancer therapies: safe and effective treatments for most or all cancers. Ann NY Acad Sci 1002:189–196
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Summerton, J.E. (2017). Invention and Early History of Morpholinos: From Pipe Dream to Practical Products. In: Moulton, H., Moulton, J. (eds) Morpholino Oligomers. Methods in Molecular Biology, vol 1565. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6817-6_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6817-6_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6815-2
Online ISBN: 978-1-4939-6817-6
eBook Packages: Springer Protocols